Last reviewed · How we verify

N2O exposure — Competitive Intelligence Brief

N2O exposure (N2O exposure) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhalational anesthetic gas. Area: Anesthesiology; Pain Management.

marketed Inhalational anesthetic gas NMDA receptor (non-competitive antagonist); GABA receptors; opioid receptors Anesthesiology; Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

N2O exposure (N2O exposure) — Maisonneuve-Rosemont Hospital. Nitrous oxide (N2O) is an inhaled anesthetic gas that depresses the central nervous system by modulating NMDA receptors and other ion channels to produce anesthesia and analgesia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
N2O exposure TARGET N2O exposure Maisonneuve-Rosemont Hospital marketed Inhalational anesthetic gas NMDA receptor (non-competitive antagonist); GABA receptors; opioid receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhalational anesthetic gas class)

  1. Maisonneuve-Rosemont Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). N2O exposure — Competitive Intelligence Brief. https://druglandscape.com/ci/n2o-exposure. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: